Evidence map›Paper›PMID 42565586›Full record

ArticleMicrobiology spectrum2026

Real-world outcomes of cefepime/enmetazobactam for Enterobacterales infections: a retrospective descriptive study.

Cecilia Bonazzetti, Marco Falcone, Giusy Tiseo, Francesco Di Gennaro, Luisa Frallonardo, Annalisa Saracino, Sara Tedeschi, Sergio Lo Caputo, Irene Francesca Bottalico, Filippo Del Puente and 20 more

Abstract readMulticenter Study
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Cecilia BonazzettiInfectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.ORCID 0000-0002-5661-1324
Marco FalconeInfectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.ORCID 0000-0003-3813-8796
Giusy TiseoInfectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Pisa, Italy.ORCID 0000-0002-3884-4933
Francesco Di GennaroDepartment of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, Italy.ORCID 0000-0003-3453-5647
Luisa FrallonardoDepartment of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, Italy.
Annalisa SaracinoDepartment of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, Italy.ORCID 0000-0001-9558-208X
Sara TedeschiInfectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Sergio Lo CaputoClinic of Infectious Diseases, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Irene Francesca BottalicoClinic of Infectious Diseases, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Filippo Del PuenteDepartment of Infectious Diseases, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
Emanuele PontaliDepartment of Infectious Diseases, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
Alessandro CilliInfectious Disease Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Linda BussiniInfectious Disease Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Michele BartolettiInfectious Disease Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Alessandro RussoDepartment of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy.
Luca PipitoDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy.
Antonio CascioDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G D'Alessandro", University of Palermo, Palermo, Italy.ORCID 0000-0002-1992-1796
Ilaria De BenedettoDepartment of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
Silvia CorcioneDepartment of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
Francesco Giuseppe De RosaDepartment of Medical Sciences, Infectious Diseases, University of Turin, Turin, Italy.
Alberto FareseInfectious Diseases Clinic, Careggi University Hospital, Firenze, Italy.
Bruno ViaggiIntensive Care Unit CTO, Careggi University Hospital, Firenze, Italy.
Alessandra OlivaDepartment of Public Health and Infectious Diseases, Sapienza Università di Roma, Rome, Italy.ORCID 0000-0003-0832-7975
Claudio MastroianniDepartment of Public Health and Infectious Diseases, Sapienza Università di Roma, Rome, Italy.ORCID 0000-0002-1286-467X
Martina RanzenigoUnit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Antonella CastagnaUnit of Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Fabrizio PulvirentiUnit of Infectious Diseases, Gela Hospital, Gela, Italy.
Luca GuerraInfectious Diseases Unit, Department for Integrated Infectious Risk Management, IRCCS Policlinico S. Orsola-Malpighi Hospital, AUSL Bologna-IRCCS IOR Bologna-AUSL, Imola, Italy.
Maddalena GiannellaInfectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Pierluigi VialeInfectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cefepime/enmetazobactam (FEP/META) is a novel β-lactam/β-lactamase inhibitor combination with activity against Enterobacterales, including extended-spectrum β-lactamase-producing isolates, but real-world clinical data outside randomized trials remain limited. We conducted a retrospective multicenter descriptive study across 13 Italian hospitals. Eligible patients had infections caused by Enterobacterales and received ≥72 h of cefepime/enmetazobactam therapy (alone or in combination with other antimicrobials) under a compassionate-use program. Thirty-two patients were included. The most frequently isolated pathogens were

Indexed as

Anti-Bacterial Agentsbeta-Lactamase InhibitorsCefepimeEnterobacteriaceaeEnterobacteriaceae InfectionsAgedAged, 80 and overAzabicyclo Compoundsbeta-LactamasesEscherichia coliFemaleHumansItalyKlebsiella pneumoniaeMaleMicrobial Sensitivity TestsAnti-Bacterial AgentsAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesCefepimeenmetazobactamTriazolescefepime/enmetazobactamextended-spectrum beta-lactamasegram-negative

Identifiers

PMID42565586
PMCPMC13532315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.